 |
Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received prior (K)RAS-targeted therapy
BURLINGTON, Mass., Nov. 3, 2026 /PRNewswire/ — PAQ Therapeutics, a clinical-stage biotechnology company developing targeted protein degraders for KRAS-driven cancers with significant unmet medical need, today announced that first clinical data for PT0253, its selective KRAS G12D degrader, will be presented in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18–20 in Barcelona, Spain. The presentation will report findings from the company’s ongoing Phase 1 trial in patients with advanced solid tumors. PAQ will also present a poster describing the preclinical profile of PT0253.
ENA 2026 Presentations
Late-Breaking Oral Presentation
Abstract 6LBA: PT0253, a selective KRAS G12D degrader, shows a differentiated safety profile and antitumor activity, including after prior (K)RAS therapy, in advanced solid tumors
Session: Plenary Session 6 – Proffered Papers: Advances in Targeting RAS
Date/Time: Friday, November 20, 2026, 12:36–12:44 p.m. CET
Authors: Leontios Pappas, William B. McKean, Alexander I. Spira (Presenting Author), Drew W. Rasco, Ildefonso I. Rodriguez-Rivera, Anthony Tolcher, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Joon Oh Park, Heung-Moon Chang, Hong Jae Chon, Huaixiang Hao, Lokesh Gakhar, Joseph Donahue, Adam Shilling, Eric Rubin, Nan Ji, Andrew P. Krivoshik
Poster Presentation
Abstract 320: PT0253 is a potent and selective KRAS G12D degrader for treatment of cancers
Session: New Drugs
Date: Friday, November 20, 2026
Poster Board: PB-112
Authors: Huaixiang Hao, Pengrong Yan, Yuxin Wang, Fei Feng, Lokesh Gakhar, Ning Yin, Hui Qiu, Ruoxi Lan, Nan Ji
About PAQ Therapeutics
PAQ Therapeutics is a clinical-stage biotechnology company focused on advancing targeted protein degradation to address the unmet medical needs of patients with KRAS-driven cancers. Its clinical pipeline comprises PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader, both in Phase 1 development for patients with advanced solid tumors. The company is based in Burlington, Massachusetts.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
